KH7 is a soluble adenylyl cyclase (sAC)-specific inhibitor, with IC50s of 3-10 μM toward both recombinant purified human sACt protein and heterologously expressed sACt in cellular assays. KH7 is also a cAMP inhibitor.

Product information

CAS Number: 330676-02-3

Molecular Weight: 419.30

Formula: C17H15BrN4O2S

Chemical Name: 2-(1H-1,3-benzodiazol-2-ylsulfanyl)-N'-[(5-bromo-2-hydroxyphenyl)methylidene]propanehydrazide

Smiles: CC(SC1NC2=CC=CC=C2N=1)C(=O)NN=CC1=CC(Br)=CC=C1O

InChiKey: WILMXUAKQKGGCC-DJKKODMXSA-N

InChi: InChI=1S/C17H15BrN4O2S/c1-10(25-17-20-13-4-2-3-5-14(13)21-17)16(24)22-19-9-11-8-12(18)6-7-15(11)23/h2-10,23H,1H3,(H,20,21)(H,22,24)/b19-9+

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 250 mg/mL (596.23 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

KH7 (10 μM) blocks this capacitation-induced cAMP increase. At higher concentrations (50 μM), 5- to 10-fold above its IC50 but still selective for sAC relative to tmACs, KH7 resulted in a significant decrease in the basal cAMP accumulation in sperm regardless of the incubation medium. KH7 prevents the generation of CaSF. In the presence of KH7, the myocytes exerts a negative inotropic effect (NIE) of approximately 20%, suggesting that sAC is involved in the normal generation of basal cardiac contractility.

Products are for research use only. Not for human use.